

CAVELIER

ABOGADOS

WEB SITE: www.caveller-abogados.com
E-MAIL: caveller@caveller.com

EDIFICIO SISKI
CARRERA 4 No. 72 - 35
BOGOTÁ 8, COLOMBIA

TELÉFONO: (57) (1) 342.3611

SUPERINDUSTRIA Y COMERCIO

Radicación: 01009891 00000002 Folios: 11
Fecha (HH): 2001-02-01 16:47:23
Trámite: 002 PATENTES 0 1 REGISTRAR 44 RESPUESTA
Dependencia: 2000 DIVISION DE NUEVAS CREACIONES

Señora Jefe de la
DIVISION DE NUEVAS CREACIONES
Superintendencia de Industria y Comercio
E. S. D.

Referencia : Expediente No. 01.009.891
Solicitante : VERTEX PHARMACEUTICALS INCORPORATED
Asunto : Solicitud de patente para:
"DERIVADOS DE PIPERAZINA Y PIPERIDINA"
Fecha de la solicitud : 9 de febrero de 2001

TRAMITE:02 - EVENTO:01 - ACTUACION:444

1. Yo, Emilio FERRERO, obrando como apoderado del solicitante en el asunto antes identificado, me refiero al oficio número 1012, notificado por fijación en lista del 05 de abril de 2001.

Para atender a la providencia anterior solicité un plazo por medio de mi memorial número 01009891 00000002 radicado el 1 de junio de 2001.

2. Mediante el oficio número 1012 se puso en conocimiento del solicitante el informe que contiene las observaciones hechas por su Despacho sobre la presente solicitud de patente. Atiendo a las observaciones de la manera siguiente:

2.1. Documento de cesión del derecho a la patente. Presento junto con este escrito el documento de cesión de los inventores al solicitante debidamente legalizado.

2.2. Recibos. Presento junto con este escrito recibo de pago número 01-42,242 por valor de \$375.840.00 por concepto de los derechos de publicación por palabra adicional.

CAVELIER

ABOGADOS

13
377

3. Puesto que se han atendido a cabalidad las observaciones hechas por su Despacho sobre la presente solicitud de patente, atentamente solicito que se continúe su tramitación.

Bogotá, - 1 AGO. 2001

Señora Jefe,



EMILIO FERRERO
T.P.A. No. 31.929

COLO 08117-801-020-3
JJC-ID-201

214
378

PCT
ASSIGNMENT

I/We,

- (1) Ronald Charles Tomlinson,
- (2) David Laufer,
- (3) Michael Mullican

residing, respectively, at

- (1) 317 Diconzo Boulevard
Marlborough, Massachusetts, 01752 USA
- (2) 254 Taylor Road
Stow, Massachusetts, 01775 USA
- (3) 110 Parker Road
Needham, Massachusetts, 02194 USA

for good and valuable consideration, receipt of which is hereby acknowledged, have assigned, sold and transferred to, and do hereby assign, sell and transfer to VERTEX PHARMACEUTICALS INCORPORATED, a corporation organized and existing under the laws of the COMMONWEALTH OF MASSACHUSETTS and having an office and a place of business at 130 WAVERLY STREET, CAMBRIDGE, MASSACHUSETTS 02139-4242, its successors and assigns: (1) the entire right, title and interest in all countries throughout the world in and to any and all my/our inventions and discoveries disclosed in my/our International Patent

14
379

Application, filed under the Patent Cooperation Treaty in the United States Receiving Office (RO/US), entitled: "PIPERAZINE AND PIPERIDINE DERIVATIVES" and designating Albania (AL), Algeria (DZ), Antigua & Barbuda (AG), Armenia (AM), Australia (AU), Austria (AT), Azerbaijan (AZ), Barbados (BB), Belarus (BY), Belgium (BE), Benin (BJ), Bosnia and Herzegovina (BA), Brazil (BR), Bulgaria (BG), Burkina Faso (BF), Cameroon (CM), Canada (CA), Central African Republic (CF), Chad (TD), China (CN), Congo (CG), Costa Rica (CR), Côte d'Ivoire (CI), Croatia (HR), Cuba (CU), Cyprus (CY), Czech Republic (CZ), Democratic People's Republic of Korea (KP), Denmark (DK), Dominica (DM), Estonia (EE), Finland (FI), France (FR), Gabon (GA), Gambia (GM), Georgia (GE), Germany (DE), Ghana (GH), Greece (GR), Grenada (GD), Guinea (GN), Guinea Bissau (GW), Hungary (HU), Iceland (IS), India (IN), Indonesia (ID), Ireland (IE), Israel (IL), Italy (IT), Japan (JP), Kazakhstan (KZ), Kenya (KE), Kyrgyzstan (KG), Latvia (LV), Lesotho (LS), Liberia (LR), Liechtenstein (LI), Lithuania (LT), Luxembourg (LU), Madagascar (MG), former Yugoslav Republic of Macedonia (MK), Malawi (MW), Mali (ML), Mauritania (MR), Mexico (MX), Monaco (MC), Mongolia (MN), Morocco (MA), Mozambique (MZ), Netherlands (NL), New Zealand (NZ), Niger (NE), Norway (NO), Poland (PL), Portugal (PT), Republic of Korea (KR), Republic of Moldova (MD), Romania (RO), Russian Federation (RU), Saint Lucia (LC), Senegal (SN), Sierra Leone (SL), Singapore (SG), Slovakia (SK), Slovenia (SI), South Africa (ZA), Spain (ES), Sri Lanka (LK), Sudan (SD), Swaziland (SZ), Sweden (SE), Switzerland (CH), Tajikistan (TJ), Tanzania (TZ), Togo

380-
380

(TG), Trinidad and Tobago (TT), Turkey (TR), Turkmenistan (TM), Uganda (UG), Ukraine (UA), United Arab Emirates (AE), United Kingdom (GB), United States of America (US), Uzbekistan (UZ), Viet Nam (VN), Yugoslavia (YU), and Zimbabwe (ZW), [subsequently identified as International Patent Application _____, filed [_____*], including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof, and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of VERTEX PHARMACEUTICALS INCORPORATED, its designee, or in my/our names at VERTEX PHARMACEUTICALS INCORPORATED, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patent which may issue on the aforesaid inventions, discoveries and applications in any country of the world and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in and to all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the following priority application(s):

<u>60/181,944</u>	<u>United States</u>	<u>February 11, 2000</u>
application no.	country	filing date
<u>60/247,330</u>	<u>United States</u>	<u>November 10, 2000</u>
application no.	country	filing date

* I/We hereby authorize VERTEX PHARMACEUTICALS INCORPORATED and its representatives to insert in this instrument the International Patent Application number and the filing date of said application when VERTEX PHARMACEUTICALS INCORPORATED is officially notified thereof.

381

and all rights of priority in any country of the world deriving from the above-identified International Patent Application.

I/We hereby authorize and request the competent authorities to grant and to issue any and all such Letters Patent in any country throughout the world to VERTEX PHARMACEUTICALS INCORPORATED as the assignee of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by me/us had this assignment, sale and transfer not been made.

I/We agree, at any time, upon the request of VERTEX PHARMACEUTICALS INCORPORATED to execute and to deliver to VERTEX PHARMACEUTICALS INCORPORATED any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing in said inventions, discoveries or applications, and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.

I/We further agree, at any time, upon request of VERTEX PHARMACEUTICALS INCORPORATED to execute and to deliver to VERTEX PHARMACEUTICALS INCORPORATED such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect any and all rights of VERTEX PHARMACEUTICALS INCORPORATED under this Assignment,

The Commonwealth of Massachusetts

William Francis Galvin
Secretary of the Commonwealth

APOSTILLE

(Convention de La Haye du 5 octobre 1961)

1. *Country:* United States of America

This public document...

2. *has been signed by*..... **Phyllis A. Tobey**.....,

3. *acting in the capacity of*..... **Notary Public**.....,

4. *in the state of Massachusetts, whose commission expires on*

..... **May 8, 2003**

CERTIFIED

5. *at Boston, Massachusetts*

6. *on*..... **June 12, 2001**

7. *by the Secretary of the Commonwealth*

8. **182185**

9. *signed under the*

Great Seal of the Commonwealth

10. *Signature:*

William Francis Galvin

William Francis Galvin
Secretary of the Commonwealth

383

including the execution, delivery and procurement f any
and all further documents evidencing this assignment,
transfer and sale as may be necessary or desirable.

ASSIGNORS:

Ronald Charles Tomlinson (1)
Ronald Charles Tomlinson

David Lauffer (2)
David Lauffer

Michael Mullican (3)
Michael Mullican

On this 12 day of January, 2001,
Ronald Charles Tomlinson (1) personally appeared before
me, a Notary Public in and for the Commonwealth of
Massachusetts, and executed the foregoing Assignment and
duly acknowledged to me that such Assignment was executed
for the uses and purposes therein expressed.

Phyllis A. Tobey
Notary Public

On this 12 day of January, 2001,
David Lauffer (2) personally appeared before me, a Notary
Public in and for the Commonwealth of Massachusetts, and
executed the foregoing Assignment and duly acknowledged
to me that such Assignment was executed for the uses and
purposes therein expressed.

Phyllis A. Tobey
Notary Public

290
384

On this 15th day of January, 2001,
Michael Mullican (3) personally appeared before me, a
Notary Public in and for the Commonwealth of
Massachusetts, and executed the foregoing Assignment and
duly acknowledged to me that such Assignment was executed
for the uses and purposes therein expressed.

Phyllis A. Tobey
Notary Public

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003


384
385

ACKNOWLEDGEMENT OF ASSIGNEE:

VERTEX PHARMACEUTICALS INCORPORATED

By: 
Andrew S. Marks
Chief Patent Counsel

On this 18 day of JANUARY, 2001,
Andrew S. Marks personally appeared before me, a Notary
Public in and for the Commonwealth of Massachusetts, and
duly acknowledged the executed Assignment on behalf of
the Assignee.


Notary Public

PHYLLIS A. TOBEY
Notary Public
My Commission Expires May 8, 2003

NIT : 860175007-2

RECIBO OFICIAL DE CAJA : 01 - 42,242
 FECHA : JULIO 11 DE 2001

SUPERINDUSTRIA Y COMERCIO
 Radicación : 01009391 00000003 Folios: 11
 Fecha (ARD): 2001-00-01 16:47:23
 Trámite : 002 PATENTES D 1 REGISTRAL/ 444 REQUERIDA
 Dependencia: 2020 DIVISION DE NUEVOS COMERCIOS

***** CONSIGNACION *****

DEPOSITANTE	TIPO PAGO	BANCO	CUENTA	No. PAGO	FECHA PAGO	Vr. PAGO
CANELIER ABOGADOS	CONSIGNACION	BANCO POPULAR	050-00110-6	8035590	11/07/2001	10,090,350.00

***** CONCEPTO *****

CANT. CONTABILITICO	CONCEPTO	TOTAL CONCEPTO
696 50005-01-01 SOLICITUDES	9 POR PALABRA ADICIONAL (A PARTIR 3	375,340.00
	TOTAL :	375,340.00

SUM: TRESCIENTOS SETENTA Y CINCO MIL OCHOCIENTOS CUARENTA PESOS

RESPONSABLE : 

RECIBO DE CAJA APLICADO AL EXPEDIENTE No. _____

010 08117-001-020-3

Carrera 13 No. 27-00 Pisos 5, 7 y 10
 Conmutador 382 0840
 Fax 350 5220
 E-mail: info@sic.gov.co
 www.sic.gov.co
 Bogotá, D.C., Colombia



2do. EXAMEN DE FORMA PATENTE DE INVENCION

Folio 383

Radicación no 01-8891

Concepto Técnico no 1812

Clasificación Internacional de Patentes: A 61K 31/496/31/445

Practicado el examen de acuerdo a lo establecido en el Art. 38 de la Decisión 486 se determinó que esta solicitud de Patente de Invención:

- SI [☒] NO [☐] Contiene un resumen de la invención (Art.26-e).
- SI [☒] NO [☐] Contiene el título o nombre de la invención (Art.27-d).
- SI [☒] NO [☐] Contiene la descripción de la invención (Art.26-b).
- SI [☒] NO [☐] NO ES APLICABLE [☐] Contiene los dibujos necesarios para comprender la invención (Art.26-d)
- SI [☒] NO [☐] Contiene una o más reivindicaciones. (Art.26-c).
- SI [☐] NO [☐] NO ES APLICABLE [☒] Han sido desarrollados los productos y/o procedimientos a partir de recursos genéticos o de sus productos derivados de los que cualquiera de los Países Miembros es país de origen. (Art. 26- h).
- SI [☐] NO [☐] NO ES APLICABLE [☒] Los productos y/o procedimientos han sido obtenidos o desarrollados a partir de los conocimientos tradicionales de las comunidades indígenas, afroamericanas, o locales de los países miembros, de acuerdo a lo establecido en la Decisión 391 y sus modificaciones y reglamentaciones vigentes.(Art.26-i).
- SI [☐] NO [☒] La invención se refiere a un producto relativo a un material biológico. (Art.26-j).
- SI [☒] NO [☐] La prioridad coincide con la materia reivindicada.
- SI [☒] NO [☐] **CUMPLE LOS REQUISITOS TÉCNICOS**

OBSERVACIONES Y OTROS: SI [☐] NO [☒] ver hoja(s) anexa(s)

EXAMINADOR TÉCNICO
202048

Bogotá D. C., 5 de Diciembre de 2002.



2020
Bogotá DC

Doctor:
EMILIO FERRERO
Apoderado

REFERENCIA:	Radicación No.	01-9891
	Trámite	002
	Evento	001
	Actuación	418
	Oficio No.	2330
	Folios	001

Teniendo en cuenta que la solicitud de privilegio de patente que se tramita bajo el expediente indicado en la referencia, reúne los requisitos de forma establecidos en los artículos 26 y 27 de la Decisión 486 de la Comisión de la Comunidad Andina, y en las demás disposiciones vigentes sobre la materia, se envía el extracto de la solicitud a la Oficina de Comunicaciones para efecto de su publicación en la Gaceta de Propiedad Industrial, conforme lo establece el artículo 40 de la misma Decisión.

Cúmplase

Dado en Bogotá DC, a los 18 de Julio de 2002

ALIX CARMENZA CÉSPEDES DE VERGEL
Jefe de la División de Nuevas Creaciones

202048

528